124 related articles for article (PubMed ID: 9193736)
1. Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients.
Lindenmayer JP; Adityanjee ; Vital-Herne M; Bark N; Grochowski S; Moynihan N
Biol Psychiatry; 1997 Jul; 42(1):6-12. PubMed ID: 9193736
[TBL] [Abstract][Full Text] [Related]
2. Hormonal, psychological, and alcohol craving changes after m-chlorophenylpiperazine administration in alcoholics.
Buydens-Branchey L; Branchey M; Fergeson P; Hudson J; McKernin C
Alcohol Clin Exp Res; 1997 Apr; 21(2):220-6. PubMed ID: 9113256
[TBL] [Abstract][Full Text] [Related]
3. Estrogen augments serotonergic activity in postmenopausal women.
Halbreich U; Rojansky N; Palter S; Tworek H; Hissin P; Wang K
Biol Psychiatry; 1995 Apr; 37(7):434-41. PubMed ID: 7786956
[TBL] [Abstract][Full Text] [Related]
4. Hormonal responses to the administration of m-chlorophenylpiperazine in patients with seasonal affective disorder and controls.
Garcia-Borreguero D; Jacobsen FM; Murphy DL; Joseph-Vanderpool JR; Chiara A; Rosenthal NE
Biol Psychiatry; 1995 May; 37(10):740-9. PubMed ID: 7640329
[TBL] [Abstract][Full Text] [Related]
5. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures.
Stein DJ; Hollander E; DeCaria CM; Simeon D; Cohen L; Aronowitz B
Biol Psychiatry; 1996 Sep; 40(6):508-13. PubMed ID: 8879471
[TBL] [Abstract][Full Text] [Related]
6. Effect of serum cholesterol levels on meta-chlorophenylpiperazine-evoked neuroendocrine responses in healthy subjects.
Terao T; Yoshimura R; Ohmori O; Takano T; Takahashi N; Iwata N; Suzuki T; Abe K
Biol Psychiatry; 1997 May; 41(9):974-8. PubMed ID: 9110103
[TBL] [Abstract][Full Text] [Related]
7. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.
Owen RR; Gutierrez-Esteinou R; Hsiao J; Hadd K; Benkelfat C; Lawlor BA; Murphy DL; Pickar D
Arch Gen Psychiatry; 1993 Aug; 50(8):636-44. PubMed ID: 8343034
[TBL] [Abstract][Full Text] [Related]
8. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia.
Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS
Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048
[TBL] [Abstract][Full Text] [Related]
9. The meta-chlorophenylpiperazine challenge test in cocaine addicts: hormonal and psychological responses.
Buydens-Branchey L; Branchey M; Fergeson P; Hudson J; McKernin C
Biol Psychiatry; 1997 Jun; 41(11):1071-86. PubMed ID: 9146818
[TBL] [Abstract][Full Text] [Related]
10. Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval.
Nappi RE; Sances G; Brundu B; De Taddei S; Sommacal A; Ghiotto N; Polatti F; Nappi G
Hum Reprod; 2005 Dec; 20(12):3423-8. PubMed ID: 16123089
[TBL] [Abstract][Full Text] [Related]
11. The flesinoxan 5-HT1A receptor challenge in major depression and suicidal behavior.
Pitchot W; Ansseau M; Gonzalez Moreno A; Lembreghts M; Hansenne M; Wauthy J; Reel C; Jammaer R; Papart P; Sulon J
Pharmacopsychiatry; 1995 Oct; 28 Suppl 2():91-2. PubMed ID: 8614706
[TBL] [Abstract][Full Text] [Related]
12. Behavioral and neuroendocrine responses to metaCPP in anorexia nervosa.
Hadigan CM; Walsh BT; Buttinger C; Hollander E
Biol Psychiatry; 1995 Apr; 37(8):504-11. PubMed ID: 7619973
[TBL] [Abstract][Full Text] [Related]
13. The MCPP challenge test in schizophrenia: hormonal and behavioral responses.
Iqbal N; Asnis GM; Wetzler S; Kahn RS; Kay SR; van Praag HM
Biol Psychiatry; 1991 Oct; 30(8):770-8. PubMed ID: 1751620
[TBL] [Abstract][Full Text] [Related]
14. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
[TBL] [Abstract][Full Text] [Related]
15. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms.
Abi-Saab W; Seibyl JP; D'Souza DC; Karper LP; Gueorgueva R; Abi-Dargham A; Wong ML; Rajhans S; Erdos JP; Heninger GR; Charney DS; Krystal JH
Psychopharmacology (Berl); 2002 Jun; 162(1):55-62. PubMed ID: 12107618
[TBL] [Abstract][Full Text] [Related]
16. Serotonergic responsivity in trichotillomania: neuroendrocrine effects of m-chlorophenylpiperazine.
Stein DJ; Hollander E; Cohen L; Simeon D; Aronowitz B
Biol Psychiatry; 1995 Mar; 37(6):414-6. PubMed ID: 7772651
[No Abstract] [Full Text] [Related]
17. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables].
Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J
Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983
[TBL] [Abstract][Full Text] [Related]
18. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
19. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
20. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
Guise S; Soubrouillard C; Blin O
Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
